FDA Publishes Guidance on Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by Alternate Route

Summary

The FDA has released a guidance document for industry and review staff, outlining recommendations for evaluating the nonclinical safety of reformulated drug products or those administered by alternate routes, with the goal of streamlining the development process and increasing uniformity within the CDER.